Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979548 | 0.89 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL22662408 | 0.81 | SMN1; SMN2 (0.33) | SMN1; SMN2HSD17B10CYP2D6CYP2C19 | |
| SCHEMBL11982017 | 0.81 | KDM4E (0.43) | SMN1; SMN2HSD17B10CYP2D6CYP2C19 | |
| SCHEMBL21813306 | 0.75 | CYP2D6 (0.37) | CYP2D6CYP2C19 | |
| SCHEMBL6729276 | 0.75 | SMN1; SMN2 (0.38) | SMN1; SMN2HSD17B10CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL19561380 | 0.74 | CYP2D6 (0.48) | SMN1; SMN2HSD17B10CYP2D6CYP2C19FFAR1 | |
| SCHEMBL12104004 | 0.74 | — | — | |
| SCHEMBL24052902 | 0.73 | SMN1; SMN2 (0.36) | SMN1; SMN2HSD17B10ALDH1A1HTTTSHR | |
| SCHEMBL6730282 | 0.73 | ALDH1A1 (0.38) | SMN1; SMN2HSD17B10CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL18630868 | 0.73 | CYP2D6 (0.36) | SMN1; SMN2CYP2D6CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10835608-B2 | Polymer-carbohydrate conjugates for drug delivery technology | LIPOSEUTICALS INC | 2020-11-17 | — | — | US | disclosed |
| US-9175027-B2 | Polymer-carbohydrate-lipid conjugates | LIPOSEUTICALS, INC. | 2015-11-03 | — | — | US | disclosed |
| US-20120202979-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPOSEUTICALS, INC. | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10835608-B2 | Polymer-carbohydrate conjugates for drug delivery technology | LIPC, FABP4, CETP | SMN1; SMN2 3875/4885HSD17B10 147/4885CYP2D6 86/4885 |
| US-20120202979-A1 | POLYMER-CARBOHYDRATE-LIPID CONJUGATES | LIPC, FUT6, UGCG | SMN1; SMN2 4271/4885HSD17B10 157/4885CYP2D6 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.